Navigation Links
Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
Date:5/7/2008

Agreement expands Dermagraft presence within government channels

WEST PORT, Conn., and SCOTTSDALE, Ariz., May 7 /PRNewswire/ -- Advanced BioHealing, Inc. (ABH) and Regenesis Biomedical, Inc. announced today an agreement focused on the promotion of Dermagraft(R) within the United States (US) government healthcare system. Under terms of the agreement Regenesis will provide its specialized sales force to market ABH's product Dermagraft within the Veteran's Administration (VA), Department of Defense (DOD), and TriCare healthcare payer systems.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008)

"Since launching Dermagraft in 2007, we have seen the need for a focused commercial presence within government healthcare systems," said Kevin Rakin, Chairman and CEO of Advanced BioHealing. "The management team at Regenesis has developed a corporate competency in promoting and distributing advanced wound care technology within these systems. We believe this co-promotion is the most effective way to maximize reach and penetration of Dermagraft in this specialized market."

Dermagraft is a bioengineered tissue product approved by the Food and Drug Administration (FDA) for the treatment of diabetic foot ulcers (DFUs). DFUs, a complication of diabetes, affect more than 400,000 people every year in the US. If not treated properly, DFUs can result in serious infection, sometimes resulting in the need for partial or full limb amputation. There are over 100,000 amputations performed annually in the US with more than 80% owing their origin to uncontrolled infection.

"There are many wound care companies that would enjoy the opportunity to promote a product like Dermagraft," says Virginia Rybski, Acting President of Regenesis Biomedical. "ABH has done a tremendous job in promoting the product in the traditional out-patient environment. We are pleased to have the opportunity for our sales and marketing team to bring this complementary product to veterans and soldiers who will benefit from treatment of their diabetic wounds." There are more than one hundred VA and DOD medical facilities within the US. They range in treatment capability from tertiary out-patient care for military veterans and soldiers to full service in-patient facilities.

Regenesis developed and now markets the Provant(R) Wound Therapy System. Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis' proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics. For more information about Regenesis Biomedical visit http://www.Regenesisbiomedical.com

About Advanced BioHealing, Inc.

Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with corporate offices in West Port, CT and manufacturing operations in La Jolla, CA. For more information about ABH visit http://www.AdvancedBioHealing.com

For more information about Dermagraft visit http://www.Dermagraft.com

Contacts:

Advanced BioHealing, Inc.

Dean Tozer

VP Marketing & Corporate Development

DTozer@AdvancedBioHealing.com

615-260-3770

Regenesis Biomedical, Inc.

Media: Scott Robey, VP Marketing robey@regenesisbiomedical.com

Clinicians: Rick Isenberg, MD, VP Clinical Affairs

isenberg@regenesisbiomedical.com

Investors: Virginia Rybski, Acting President

rybski@regenesisbiomedical.com

http://www.regenesisbiomedical.com

480-970-4970


'/>"/>
SOURCE Regenesis Biomedical, Inc.; Advanced BioHealing, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
2. Advanced Life Sciences Announces First Quarter 2008 Financial Results
3. Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast
4. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
5. Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
6. Advanced Life Sciences Regains Compliance With Nasdaq Listing Requirements
7. Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin
8. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
9. Advanced Life Sciences Receives Nasdaq Notification
10. Advanced Life Sciences Announces Fourth Quarter and Full Year 2007 Financial Results
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Biopsies from non-small cell ... with limited tumor content in a large background of normal or wild type ... need for reliable detection of low abundance somatic mutations, particularly in small specimens ...
(Date:3/27/2017)...  Perthera,s Chief Bioinformatics Officer and research faculty member ... Ph.D., will be speaking at the American Medical Informatics ... 27, 2017, she will be speaking on the topic ... and Care" (from 10:30 a.m. – 12:00 p.m. PST) ... a participant in the "Making Precision Oncology Data More ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the world’s ... to new and improved ways of treating coronary artery disease (CAD). Lam is ...
(Date:3/27/2017)... , March 27, 2017 Neurotrope, ... novel therapies for neurodegenerative diseases, including Alzheimer,s disease, ... its application to list the Company,s common stock ... by The NASDAQ Stock Market, a unit of ... listing, Neurotrope will ring the Opening Bell at the ...
Breaking Biology Technology:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... and Reentry. "Too often, too many ... and county jails are trying to tackle this ... and friends and family members. While significant steps are ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
Breaking Biology News(10 mins):